Ankylosing spondylitis
Conference Coverage
‘Shielding’ status provides best indicator of COVID-19 mortality in U.K. arthritis population
Shielding status was the highest ranked of all the risk factors identified for early mortality from COVID-19.
News from the FDA/CDC
Upadacitinib earns FDA approval for ankylosing spondylitis
Janus kinase inhibitor offers oral option for patients who have who have had an insufficient response or intolerance with one or more tumor...
Conference Coverage
IBD risk ‘uncertain’ in biologic-treated AxSpA patients
“Enormous uncertainty” surrounds the risk of inflammatory bowel disease associated with biologic treatment in patients with axial...
From the Journals
TNF inhibitor treatment models promote personalized care in ankylosing spondylitis
A retrospective cohort study of 10 randomized, controlled trials showed the ability of baseline variables to predict response to tumor necrosis...
From the Journals
Drug survival study looks at what lasts longest in RA, axSpA, PsA, and psoriasis
Survival rates were highest for rituximab in rheumatoid arthritis and golimumab in axial spondyloarthritis in a study of two Danish registries.
Guidelines
Updated perioperative guidance says when to hold antirheumatics
Rheumatologists and orthopedic surgeons revise advice on JAK inhibitors and add new medications.
Commentary
Dietary recommendations for inflammatory rheumatic diseases
France’s first set of dietary recommendations for chronic inflammatory rheumatic diseases are a welcome guide for health care professionals and...
From the Journals
Proactive infliximab monitoring found best for sustaining control of inflammatory diseases
Proactive therapeutic drug monitoring with maintenance infliximab proved more effective in sustaining disease control than did standard care in...
News from the FDA/CDC
Tofacitinib approved for new ankylosing spondylitis indication
The action makes the drug the first Janus kinase (JAK) inhibitor to be approved for ankylosing spondylitis.
From the Journals
Peripheral manifestations make mark on spondyloarthritis trajectory
A longitudinal observational study finds differences in disease burden and activity according to presence of peripheral manifestations.
From the Journals
Axial spondyloarthritis survey raises importance of discussing treatment changes